ReviewFrontiers in immunology2020
Glycosylated Biotherapeutics: Immunological Effects of N-Glycolylneuraminic Acid.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 67 citations in OpenAlex.
- Anti-nephrin antibodies are not enriched in patients with primary and posttransplant recurrent podocytopathies.The Journal of clinical investigation · 2026Observational
- Beyond Starch: Towards a Scalable Potato Platform for Molecular Farming.Plant biotechnology journal · 2026Review
- Qualitative Characterization of Neu5Gc-Containing N-Glycans in Commercial Cheddar Cheese Products Using Nano-UHPLC-ESI-MS/MS-A Pilot Study.International journal of molecular sciences · 2026Article
- Robustness Evaluation of a Legacy N-Glycan Profiling Method for a Therapeutic Antibody Under ICH Q14 Lifecycle Principles.Antibodies (Basel, Switzerland) · 2026Article
- High Resolution Ion Mobility Enables the Separation of α-Galactose Containing Glycans from Their Non-α-Galactose Isomers.Journal of biomolecular techniques : JBT · 2026Article
- Glycoprofile Comparison of the SARS-CoV-2 Spike Proteins Expressed in CHO and HEK Cell Lines.Molecular biotechnology · 2025Article
- Highly variable aggregation and glycosylation profiles and their roles in immunogenicity to protein-based therapeutics.Journal of pharmaceutical sciences · 2025Review
- Immunogenicity risk assessment for tailored mitigation and monitoring of biotherapeutics during development: recommendations from the European Immunogenicity Platform.Frontiers in immunology · 2025Review
- A comparative guide to expression systems for phage lysin production.Essays in biochemistry · 2024Review
- Screening and Characterization of Sialic Acid-Binding Variable Lymphocyte Receptors from Hagfish.Biotech (Basel (Switzerland)) · 2024Article
- Cracking the diversity of sweet drugs.Nature chemical biology · 2024Article
- Exposing the molecular heterogeneity of glycosylated biotherapeutics.Nature communications · 2024Article
- Medical Relevance, State-of-the-Art and Perspectives of "Sweet Metacode" in Liquid Biopsy Approaches.Diagnostics (Basel, Switzerland) · 2024Review
- Characterization of an Aptamer Targeting Neu5Gc, as an Endogenous Pathogenic Factor Derived from Red Meat.Molecules (Basel, Switzerland) · 2024Article
- Serum antibody screening using glycan arrays.Chemical Society reviews · 2024Review
- A systematic review reveals conflicting evidence for the prevalence of antibodies against the sialic acid 'xenoautoantigen' Neu5Gc in humans and the need for a standardised approach to quantification.Frontiers in molecular biosciences · 2024Review
- Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies.Biotechnology advances · 2023Review
- Engineering Human Cells Expressing CRISPR/Cas9-Synergistic Activation Mediators for Recombinant Protein Production.International journal of molecular sciences · 2023Article
- Innovative Metrics for Reporting and Comparing the Glycan Structural Profile in Biotherapeutics.Molecules (Basel, Switzerland) · 2023Article
- Metabonomic analysis of human and 12 kinds of livestock mature milk.Food chemistry: X · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emerging field of biotherapeutics provides successful treatments for various diseases, yet immunogenicity and limited efficacy remain major concerns for many products. Glycosylation is a key factor determining the pharmacological properties of biotherapeutics, including their stability, solubility, bioavailability, pharmacokinetics, and immunogenicity. Hence, an increased attention is directed at optimizing the glycosylation properties of biotherapeutics. Currently, most biotherapeutics are produced in non-human mammalian cells in light of their ability to produce human-like glycosylation. However, most mammals produce the sialic acid
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.